Pre-clinical studies of cultured meningioma cell lines from NF2 found targeting of the histone deacetylase (HDAC)resulted in decreased AKT activation and decreased cellular growth, as well as, decreased tumor size in mouse models. The gene discussed is HDAC9; the disease is neoplasm.